Floatz logo

Anti-Cea-Car T

Metastasis From Malignant Tumor Of Colon

Ruijin HospitalCell therapyEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

34 Active assets in the Metastasis From Malignant Tumor Of Colon cohort.

Asset / SponsorPhaseRating
Eloxatin
Fudan University
Phase 4BBB
Fruquintinib
Peking University
Phase 3BBB
DEXAMETHASONE
Fudan University
Phase 3BB
Capecitabine
Jun Huang
Phase 3BB
Irinotecan
Jun Huang
Phase 3BB

View all 50 →

Same molecule, other indications

Anti-Cea-Car T is also rated in:

colorectal cancerDormant
CC
Indicative ·
41 / 100
View asset →
lung cancerDormant
C
Indicative ·
37 / 100
View asset →
gastric cancerDormant
C
Indicative ·
37 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →